image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 1.27
-5.22 %
$ 205 M
Market Cap
127.0
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one IRWD stock under the worst case scenario is HIDDEN Compared to the current market price of 1.27 USD, Ironwood Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one IRWD stock under the base case scenario is HIDDEN Compared to the current market price of 1.27 USD, Ironwood Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one IRWD stock under the best case scenario is HIDDEN Compared to the current market price of 1.27 USD, Ironwood Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart IRWD

image
$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
351 M REVENUE
-20.63%
93.1 M OPERATING INCOME
109.85%
880 K NET INCOME
100.09%
104 M OPERATING CASH FLOW
-43.55%
-142 K INVESTING CASH FLOW
99.99%
-107 M FINANCING CASH FLOW
-38.60%
90.5 M REVENUE
-1.14%
33.2 M OPERATING INCOME
29.57%
2.26 M NET INCOME
-38.12%
15.2 M OPERATING CASH FLOW
53.91%
0 INVESTING CASH FLOW
100.00%
-14.9 M FINANCING CASH FLOW
45.18%
Balance Sheet Ironwood Pharmaceuticals, Inc.
image
Current Assets 182 M
Cash & Short-Term Investments 88.6 M
Receivables 81.9 M
Other Current Assets 11.9 M
Non-Current Assets 169 M
Long-Term Investments 0
PP&E 15.5 M
Other Non-Current Assets 153 M
25.24 %23.34 %3.40 %4.42 %43.61 %Total Assets$350.9m
Current Liabilities 38.8 M
Accounts Payable 2.13 M
Short-Term Debt 3.19 M
Other Current Liabilities 33.5 M
Non-Current Liabilities 211 M
Long-Term Debt 224 M
Other Non-Current Liabilities -12.3 M
13.40 %89.39 %Total Liabilities$250.1m
EFFICIENCY
Earnings Waterfall Ironwood Pharmaceuticals, Inc.
image
Revenue 351 M
Cost Of Revenue 0
Gross Profit 351 M
Operating Expenses 258 M
Operating Income 93.1 M
Other Expenses 92.2 M
Net Income 880 K
400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m00351m0351m(258m)93m(92m)880kRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
26.50% OPERATING MARGIN
26.50%
0.25% NET MARGIN
0.25%
0.87% ROE
0.87%
0.25% ROA
0.25%
0.40% ROIC
0.40%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Ironwood Pharmaceuticals, Inc.
image
300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 880 K
Depreciation & Amortization 2.01 M
Capital Expenditures -142 K
Stock-Based Compensation 29.8 M
Change in Working Capital 739 K
Others -24.3 M
Free Cash Flow 103 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Ironwood Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for IRWD of $11.2 , with forecasts ranging from a low of $5 to a high of $18 .
IRWD Lowest Price Target Wall Street Target
5 USD 293.70%
IRWD Average Price Target Wall Street Target
11.2 USD 781.89%
IRWD Highest Price Target Wall Street Target
18 USD 1317.32%
Price
Max Price Target
Min Price Target
Average Price Target
181816161414121210108866442200May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Ironwood Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
428 K USD 5
3-6 MONTHS
66.8 K USD 2
6-9 MONTHS
55.6 K USD 2
9-12 MONTHS
1.46 M USD 6
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (the “Company”) (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that it received a notification letter (the “Notice”) on March 21, 2025 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company's delay in filing its Annual Report on Form 10-K fo. businesswire.com - 3 weeks ago
Industry Veteran Launches Ironwood III With Substantial Equity Commitment From Kayne Anderson Energy Infrastructure Fund SAN ANTONIO--(BUSINESS WIRE)--Ironwood Midstream Energy Partners III, LLC (Ironwood III) today announced it has secured a substantial equity commitment from Kayne Anderson Energy Infrastructure Fund, Inc. (KYN). Led by industry veteran Mike Williams, Ironwood III has a long-term operating strategy, focused on the acquisition, development, and operation of top-tier midstream assets in the most economic and desirable oil and gas producing regions in the United States. In conjunction with the equi. businesswire.com - 3 weeks ago
Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks If you work in the biotech industry, you might know the name Alex Denner. 247wallst.com - 1 month ago
IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down Ironwood reports weaker-than-expected results for the fourth quarter of 2024. The company maintains total revenue guidance for 2025. zacks.com - 1 month ago
Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2024 Earnings Call Transcript Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Greg Martini - Chief Financial Officer Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Jason Butler - Citizens JMP Matt Cowper - Leerink Partners David Amsellem - Piper Sandler Operator My name is Kathleen, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals Fourth Quarter 2024 Investor Update Conference Call. seekingalpha.com - 1 month ago
Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to break-even earnings per share a year ago. zacks.com - 1 month ago
Millrose Properties Set to Join S&P SmallCap 600 NEW YORK , Feb. 5, 2025 /PRNewswire/ -- Millrose Properties Inc. (NYSE: MRP) will replace Ironwood Pharmaceuticals Inc. (NASD: IRWD) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 10. S&P 500 constituent Lennar Corp (NYSE: LEN) is spinning off Millrose Properties in a transaction expected to be completed on Friday, February 7. prnewswire.com - 2 months ago
IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls Ironwood begins the rolling NDA filing for apraglutide to treat short bowel syndrome patients dependent on parenteral support. zacks.com - 2 months ago
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications The Biden administration unveiled the next 15 prescription drugs that will be subject to price negotiations between manufacturers and Medicare. It kicks off the second phase of a landmark provision in the Inflation Reduction Act that aims to make costly medications more affordable for seniors. cnbc.com - 3 months ago
Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET at the Lotte New York Palace. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the confe. businesswire.com - 4 months ago
Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 7:30 a.m. GT at the Waldorf Hilton in London. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be a. businesswire.com - 5 months ago
Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down IRWD's third-quarter earnings miss estimates while revenues beat the same. The company maintains revenue guidance for 2024. zacks.com - 5 months ago
8. Profile Summary

Ironwood Pharmaceuticals, Inc. IRWD

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 205 M
Dividend Yield 0.00%
Description Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Contact 100 Summer Street, Boston, MA, 02110 https://www.ironwoodpharma.com
IPO Date Feb. 3, 2010
Employees 253
Officers Dr. Rosario Lobrutto M.B.A., M.S., Ph.D. Vice President & Global Head of Technical Operations Dr. Michael Shetzline M.D., Ph.D. Chief Medical Officer, Senior Vice President and Head of Research & Drug Development Mr. Mike Nanfito Vice President of Sales & Sales Excellence Tammi Gaskins Senior Vice President & Chief Commercial Officer. Mr. Matt Roache Director of Investor Relations Mr. Thomas A. McCourt Chief Executive Officer & Director Mr. John Minardo Senior Vice President, Chief Legal Officer & Secretary